Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

被引:2
|
作者
Akuta, Norio [1 ,2 ]
Suzuki, Fumitaka [2 ]
Seko, Yuya [2 ]
Kawamura, Yusuke [2 ]
Sezaki, Hitomi [2 ]
Suzuki, Yoshiyuki [2 ]
Hosaka, Tetsuya [2 ]
Kobayashi, Masahiro [2 ]
Kobayashi, Mariko [3 ]
Saitoh, Satoshi [2 ]
Arase, Yasuji [2 ]
Ikeda, Kenji [2 ]
Kumada, Hiromitsu [2 ]
机构
[1] Toranomon Gen Hosp, Dept Hepatol, Minato Ku, Tokyo 1050001, Japan
[2] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo 1050001, Japan
[3] Toranomon Gen Hosp, Liver Res Lab, Tokyo 1050001, Japan
关键词
Hepatitis C virus; Interferon; Ribavirin; Hepatocellular carcinoma; Cirrhosis; Biochemical response; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; AMINO-ACID SUBSTITUTIONS; CHRONIC HCV INFECTION; HEPATOCELLULAR-CARCINOMA; CORE REGION; GENOTYPE; CONTROLLED TRIAL; LIVER-DISEASE; TELAPREVIR; PEGINTERFERON;
D O I
10.1159/000342746
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objective: Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear. Methods: In study 1, in 157 consecutive patients with HCV-related compensated cirrhosis, treatment efficacy with interferon plus ribavirin therapy was evaluated for 48 weeks of HCV genotype 1b (HCV-1b) or 24 weeks of HCV-2a/2b. In study 2, in 185 consecutive patients with HCV-related compensated cirrhosis, who showed no sustained virological response following the first course of interferon monotherapy, hepatocarcinogenesis rates were evaluated according to the additional treatment, and they were classified into three groups: no treatment, interferon monotherapy, and ribavirin combination therapy. Results: In study 1, in HCV-1b, rates of sustained virological response and sustained biochemical response were 21 and 56%, respectively. In HCV-2a/2b, rates of sustained virological response and sustained biochemical response were 70 and 78%, respectively. In HCV-1b, sustained biochemical response rates were significantly higher than those of sustained virological response. In study 2, the hepatocarcinogenesis rates in ribavirin combination therapy were significantly lower than those in interferon monotherapy and no treatment, respectively. Conclusion: Ribavirin combination therapy for HCV-related compensated cirrhosis reduces the risk of hepatocarcinogenesis in comparison with interferon monotherapy, and higher rates of sustained biochemical response might be associated with lower hepatocarcinogenesis rates. Copyright (c) 2012 S. Karger AG, Basel
引用
收藏
页码:37 / 45
页数:9
相关论文
共 50 条
  • [1] Determinants of outcome of compensated hepatitis C virus-related cirrhosis
    Serfaty, L
    Aumaître, H
    Chazouillères, O
    Bonnand, AM
    Rosmorduc, O
    Poupon, RE
    Poupon, R
    [J]. HEPATOLOGY, 1998, 27 (05) : 1435 - 1440
  • [2] Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2
    Hasegawa, Eiko
    Kobayashi, Masahiro
    Kawamura, Yusuke
    Yatsuji, Hiromi
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Akuta, Norio
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. HEPATOLOGY RESEARCH, 2007, 37 (10) : 793 - 800
  • [3] Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
    Flamm, Steven
    Lawitz, Eric
    Borg, Brian
    Charlton, Michael
    Landis, Charles
    Reddy, K. Rajender
    Shiffman, Mitchell
    Alsina, Angel
    Chang, Charissa
    Ravendhran, Natarajan
    Hernandez, Candido
    Hezode, Christophe
    Scherbakovsky, Stacey
    Mercier, Renee-Claude
    Samuel, Didier
    [J]. VIRUSES-BASEL, 2023, 15 (10):
  • [4] Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia
    Karakan, T
    Cindoruk, M
    Degertekin, B
    Dogan, I
    Sancak, A
    Dumlu, S
    Gorgul, A
    Unal, S
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (03): : 247 - 253
  • [5] Reversibility of hepatitis C virus-related cirrhosis
    Pol, S
    Carnot, F
    Nalpas, B
    Lagneau, JL
    Fontaine, H
    Serpaggi, J
    Serfaty, L
    Bedossa, P
    Bréchot, C
    [J]. HUMAN PATHOLOGY, 2004, 35 (01) : 107 - 112
  • [6] Lack of clinical benefit of direct acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis
    Berge, E.
    Arencibia, A.
    Oton, E.
    Marquez, A.
    Cejas, L.
    Acosta, S.
    Perez, F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S311 - S311
  • [7] Treatment of hepatitis C virus-related cirrhosis
    Bronowicki, JP
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2002, 26 : B220 - B224
  • [8] Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
    Guo-Cai Lv
    Jin-Mei Yao
    Yi-Da Yang
    Lin Zheng
    Ji-Fang Sheng
    Yu Chen
    Lan-Juan Li
    [J]. World Journal of Gastroenterology, 2013, (22) : 3481 - 3486
  • [9] Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
    Lv, Guo-Cai
    Yao, Jin-Mei
    Yang, Yi-Da
    Zheng, Lin
    Sheng, Ji-Fang
    Chen, Yu
    Li, Lan-Juan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (22) : 3481 - 3486
  • [10] Alcohol intake increases the risk of hepatocellular carcinoma in hepatitis C virus-related compensated cirrhosis
    Deltenre, Pierre
    Vandenbulcke, Helene
    Marot, Astrid
    Doerig, Christopher
    Henrion, Jean
    Moreno, Christophe
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 15S - 15S